RESUMEN
BACKGROUND: Human immunodeficiency virus (HIV) infection is associated with chronic immune activation, and concurrent sexually transmitted infections (STIs) may increase immune activation. OBJECTIVES: Because HIV-infected youth are at high risk of STIs and little is known about the impact of STIs on immune activation in HIV-infected youth, we conducted an exploratory study examining the association between STIs and systemic inflammation and immune activation among HIV-infected adolescents. STUDY DESIGN: Forty-nine behaviorally infected U.S. youth ages 18-24 years with baseline CD4+ T-cells >350 who maintained viral suppression on therapy by week 48 were included. Evaluation for STIs (herpes simplex virus [HSV], Chlamydia trachomatis, syphilis, Neisseria gonorrhoeae) was conducted as standard of care and reported on case report forms. Measures of T-cell subsets, systemic immune activation, and soluble factors were examined at week 48 for differences between participants with an STI diagnosis during the 48 weeks compared to those without an STI. RESULTS: Forty-three participants (88%) were male; 57% had baseline CD4+ T-cell counts >500 cells/mm3. Eighteen youth were reported to have ≥1 STI. At week 48, participants with STIs demonstrated lower CD4+ T-cell counts (any STI vs. no STI, pâ¯=â¯0.024; HSV vs. no STI, pâ¯=â¯0.022) and evidence of increased systemic immune activation, including higher CD57 intensity, higher HLA-DR intensity, and lower CD28 percentage, when compared to those without STIs. There were no differences in soluble factors between STI groups. CONCLUSIONS: Results indicate novel activation of CD4+ T-cells among HIV-infected youth who have STIs other than HSV, which may contribute to disease progression.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Activación de Linfocitos , Enfermedades de Transmisión Sexual/inmunología , Adolescente , Terapia Antirretroviral Altamente Activa , Recuento de Linfocito CD4 , Linfocitos T CD4-Positivos/inmunología , Femenino , Infecciones por VIH/complicaciones , Humanos , Masculino , Enfermedades de Transmisión Sexual/complicaciones , Enfermedades de Transmisión Sexual/epidemiología , Subgrupos de Linfocitos T/inmunología , Estados Unidos/epidemiología , Adulto JovenRESUMEN
INTRODUCTION: Colorectal cancer is a leading cause of cancer-related death in the U.S. Although screening reduces colorectal cancer incidence and mortality, screening rates among U.S. adults remain less than optimal, especially among disadvantaged populations. This study examined the efficacy of patient navigation to increase colonoscopy screening. STUDY DESIGN: RCT. SETTING/PARTICIPANTS: A total of 843 low-income adults, primarily Hispanic and non-Hispanic blacks, aged 50-75 years referred for colonoscopy at Boston Medical Center were randomized into the intervention (n=429) or control (n=427) groups. Participants were enrolled between September 2012 and December 2014, with analysis following through 2015. INTERVENTION: Two bilingual lay navigators provided individualized education and support to reduce patient barriers and facilitate colonoscopy completion. The intervention was delivered largely by telephone. MAIN OUTCOME MEASURE: Colonoscopy completion within 6 months of study enrollment. RESULTS: Colonoscopy completion was significantly higher for navigated patients (61.1%) than control group patients receiving usual care (53.2%, p=0.021). Based on regression analysis, the odds of completing a colonoscopy for navigated patients was one and a half times greater than for controls (95% CI=1.12, 2.03, p=0.007). There were no differences between navigated and control groups in regard to adequacy of bowel preparation (95.3% vs 97.3%, respectively). CONCLUSIONS: Navigation significantly improved colonoscopy screening completion among a racially diverse, low-income population. Results contribute to mounting evidence demonstrating the efficacy of patient navigation in increasing colorectal cancer screening. Screening can be further enhanced when navigation is combined with other evidence-based practices implemented in healthcare systems and the community.
Asunto(s)
Neoplasias Colorrectales/diagnóstico por imagen , Detección Precoz del Cáncer/métodos , Tamizaje Masivo/métodos , Navegación de Pacientes/métodos , Centros Médicos Académicos/estadística & datos numéricos , Anciano , Boston , Colonoscopía/estadística & datos numéricos , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/prevención & control , Detección Precoz del Cáncer/estadística & datos numéricos , Femenino , Disparidades en Atención de Salud/estadística & datos numéricos , Humanos , Incidencia , Masculino , Tamizaje Masivo/estadística & datos numéricos , Persona de Mediana Edad , Sangre Oculta , Navegación de Pacientes/estadística & datos numéricos , Pobreza/estadística & datos numéricos , Evaluación de Programas y Proyectos de Salud , Derivación y Consulta/estadística & datos numéricos , Autoinforme , Factores SocioeconómicosRESUMEN
Atrocious events seem to have multiplied in frequency recently. Sometimes it feels as if we have become almost inured to their obscenity. No sooner has the impact and aftermath of one event receded into the past than along comes another to test our reserves.
RESUMEN
OBJECTIVE: Exercise intolerance afflicts Fontan patients with total cavopulmonary connections (TCPCs) causing a reduction in quality of life. Optimising TCPC design is hypothesised to have a beneficial effect on exercise capacity. This study investigates relationships between TCPC geometries and exercise haemodynamics and performance. METHODS: This study included 47 patients who completed metabolic exercise stress test with cardiac magnetic resonance (CMR). Phase-contrast CMR images were acquired immediately following supine lower limb exercise. Both anatomies and exercise vessel flow rates at ventilatory anaerobic threshold (VAT) were extracted. The vascular modelling toolkits were used to analyse TCPC geometries. Computational simulations were performed to quantify TCPC indexed power loss (iPL) at VAT. RESULTS: A highly significant inverse correlation was found between the TCPC diameter index, which factors in the narrowing of TCPC vessels, with iPL at VAT (r=-0.723, p<0.001) but positive correlations with exercise performance variables, including minute oxygen consumption (VO2) at VAT (r=0.373, p=0.01), VO2 at peak exercise (r=0.485, p=0.001) and work at VAT/weight (r=0.368, p=0.01). iPL at VAT was negatively correlated with VO2 at VAT (r=-0.337, p=0.02), VO2 at peak exercise (r=-0.394, p=0.007) and work at VAT/weight (r=-0.208, p=0.17). CONCLUSIONS: Eliminating vessel narrowing in TCPCs and reducing elevated iPL at VAT could enhance exercise tolerance for patients with TCPCs. These findings could help plan surgical or catheter-based strategies to improve patients' exercise capacity.
Asunto(s)
Tolerancia al Ejercicio , Ejercicio Físico , Procedimiento de Fontan/efectos adversos , Cardiopatías Congénitas/cirugía , Hemodinámica , Adolescente , Umbral Anaerobio , Prueba de Esfuerzo , Femenino , Cardiopatías Congénitas/diagnóstico , Cardiopatías Congénitas/fisiopatología , Humanos , Imagen por Resonancia Magnética , Masculino , Modelos Cardiovasculares , Consumo de Oxígeno , Modelación Específica para el Paciente , Calidad de Vida , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: Preliminary test of a manualized, measurement-guided treatment for depression for adolescents and young adults in care at 4 sites of the Adolescent Trials Network for HIV/AIDS Interventions. DESIGN: The US sites were randomly assigned to either a 24-week, combination cognitive behavioral therapy and medication management algorithm (COMB) tailored for youth living with HIV (YLWH) or to treatment as usual (TAU). METHODS: Youth at TAU sites had access to therapists and medication management as needed. COMB-site clinicians were trained in the manualized intervention and participated in supervision calls to monitor intervention fidelity. RESULTS: Over the course of the study with 44 participants, those in COMB, compared with those in TAU, reported fewer depressive symptoms, P < 0.01 (as measured by the Quick Inventory for Depression symptoms) and were more likely to be in remission, P < 0.001 (65% vs. 10% at week 24, end of treatment, and 71% vs. 7% at week 48, final follow-up). A greater proportion of COMB participants received psychotherapy (95% vs. 45%, P < 0.001) and attended more sessions (12.6 vs. 5, P < 0.001) than those in TAU. Viral load decreased in both groups and was associated (P < 0.05) with reduction in depressive symptoms. CONCLUSIONS: A 24-week manualized, measurement-guided psychotherapy and medication management algorithm tailored for YLWH was more effective in achieving and sustaining remission from depression than TAU at HIV care clinic sites. Given observed treatment efficacy, this structured combination treatment could be disseminated to medical clinics to successfully treat YLWH, who are at particular risk for depression.
Asunto(s)
Antidepresivos/uso terapéutico , Terapia Cognitivo-Conductual/métodos , Trastorno Depresivo/terapia , Infecciones por VIH/psicología , Adolescente , Adulto , Instituciones de Atención Ambulatoria/estadística & datos numéricos , Terapia Combinada , Trastorno Depresivo/etiología , Femenino , Humanos , Masculino , Cumplimiento de la Medicación/estadística & datos numéricos , Escalas de Valoración Psiquiátrica , Adulto JovenRESUMEN
Although youth living with behaviorally acquired HIV (YLWH) are at risk for cognitive impairments, the relationship of impairments to HIV and potential to improve with antiretroviral therapy (ART) are unclear. This prospective observational study was designed to examine the impact of initiation and timing of ART on neurocognitive functioning in YLWH in the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Treatment naïve YLWH age 18-24 completed baseline and four additional assessments of attention/working memory, complex executive, and motor functioning over 3 years. Group 1 co-enrolled in an early ART initiation study and initiated ART at enrollment CD4 >350 (n = 56); group 2 had CD4 >350 and were not initiating ART (n = 66); group 3 initiated ART with CD4 <350 (n = 59) per standard of care treatment guidelines at the time. Treatment was de-intensified to boosted protease inhibitor monotherapy at 48 weeks for those in group 1 with suppressed viral load. Covariates included demographic, behavioral, and medical history variables. Analyses used hierarchical linear modeling. All groups showed improved performance with peak at 96 weeks in all three functional domains. Trajectories of change were not significantly associated with treatment, timing of treatment initiation, or ART de-intensification. Demographic variables and comorbidities were associated with baseline functioning but did not directly interact with change over time. In conclusion, YLWH showed improvement in neurocognitive functioning over time that may be related to practice effects and nonspecific impact of study participation. Neither improvement nor decline in functioning was associated with timing of ART initiation or therapy de-intensification.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Disfunción Cognitiva/tratamiento farmacológico , Infecciones por VIH/tratamiento farmacológico , Modelos Estadísticos , Adolescente , Terapia Antirretroviral Altamente Activa , Atención/efectos de los fármacos , Recuento de Linfocito CD4 , Disfunción Cognitiva/complicaciones , Disfunción Cognitiva/fisiopatología , Disfunción Cognitiva/virología , Esquema de Medicación , Función Ejecutiva/efectos de los fármacos , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/fisiopatología , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , VIH-1/fisiología , Humanos , Masculino , Memoria a Corto Plazo/efectos de los fármacos , Pruebas Neuropsicológicas , Estudios Prospectivos , Desempeño Psicomotor/efectos de los fármacos , Factores de Tiempo , Carga Viral/efectos de los fármacos , Adulto JovenAsunto(s)
Rodilla/fisiopatología , Traumatismos de los Tejidos Blandos/diagnóstico , Traumatismos de los Tejidos Blandos/terapia , Adulto , Fracturas por Avulsión/complicaciones , Fracturas por Avulsión/diagnóstico , Marcha/fisiología , Humanos , Masculino , Traumatismos de los Tejidos Blandos/complicacionesRESUMEN
BACKGROUND: Measures of immune outcomes in youth who initiate combination antiretroviral therapy (cART) early in HIV infection are limited. DESIGN: Adolescent Trials Network 061 examined changes over 48 weeks of cART in T-cell subsets and markers of T-cell and macrophage activation in subjects with pre-therapy CD4 > 350 cells/mm. All subjects had optimal viral suppression from weeks 24 through 48. METHODS: Subjects (n = 48) initiated cART with tenofovir/emtricitabine plus ritonavir-boosted atazanavir. Data were collected at baseline and weeks 12, 24, and 48. Trends were compared to uninfected controls. RESULTS: Significant increases over 48 weeks were noted in all CD4 populations, including total, naive, central memory (CM), and effector memory RO (EM RO) and effector memory RA (EM RA), whereas numbers of CM and EM RO CD8 cells declined significantly. By week 48, CD4 naive cells were similar to controls, whereas CM CD4 cells remained significantly lower and EM RO and EM RA subsets were significantly higher. CD38 and HLA DR expression, both individually and when co-expressed, decreased over 48 weeks of cART on CD8 cells but remained significantly higher than controls at week 48. In contrast, markers of macrophage activation measured by sCD14 and sCD163 in plasma did not change with cART and were significantly higher than controls. CONCLUSIONS: In youth initiating early cART, CD4 cell reconstitution is robust with decreases in CD8 cells. However, CD8 T-cell and macrophage activation persists at higher levels than uninfected controls.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Infecciones por VIH/tratamiento farmacológico , Activación de Linfocitos , Activación de Macrófagos , Adolescente , Estudios de Cohortes , Femenino , Humanos , Masculino , Factores de Tiempo , Adulto JovenRESUMEN
BACKGROUND: Single ventricle lesions are associated with gradual attrition after surgical palliation with the total cavopulmonary connection (TCPC). Ventricular dysfunction is frequently noted, particularly impaired diastolic performance. This study seeks to relate TCPC hemodynamic energy losses to single ventricle volumes and filling characteristics. METHODS: Cardiac magnetic resonance (CMR) data were retrospectively analyzed for 30 single ventricle patients at an average age of 12.7 ± 4.8 years. Cine ventricular short-axis scans were semiautomatically segmented for all cardiac phases. Ventricular volumes, ejection fraction, peak filling rate, peak ejection rate, and time to peak filling were calculated. Corresponding patient-specific TCPC geometry was acquired from a stack of transverse CMR images; relevant flow rates were segmented from through-plane phase contrast CMR data at TCPC inlets and outlets. The TCPC indexed power loss was calculated from computational fluid dynamics simulations using a validated custom solver. Time-averaged flow conditions and rigid vessel walls were assumed in all cases. Pearson correlations were used to detect relationships between variables, with p less than 0.05 considered significant. RESULTS: Ventricular end-diastolic (R = -0.48) and stroke volumes (R = -0.37) had significant negative correlations with the natural logarithm of a flow-independent measure of power loss. This power loss measure also had a significant positive relationship to time to peak filling rate (normalized to cycle time; R = 0.67). CONCLUSIONS: Flow-independent TCPC power loss is inversely related with ventricular end-diastolic and stroke volumes. Elevated power losses may contribute to impaired diastolic filling and limited preload reserve in single ventricle patients.
Asunto(s)
Procedimiento de Fontan , Ventrículos Cardíacos/anomalías , Ventrículos Cardíacos/cirugía , Hemodinámica , Disfunción Ventricular/fisiopatología , Niño , Femenino , Ventrículos Cardíacos/fisiopatología , Humanos , Masculino , Estudios Retrospectivos , Volumen SistólicoRESUMEN
OBJECTIVE: Elevated energy loss in the total cavopulmonary connection (TCPC) is hypothesised to have a detrimental effect on clinical outcomes in single-ventricle physiology, which may be magnified with exercise. This study investigates the relationship between TCPC haemodynamic energy dissipation and exercise performance in single-ventricle patients. METHODS: Thirty consecutive Fontan patients with TCPC and standard metabolic exercise testing were included. Specific anatomies and flow rates at rest and exercise were obtained from cardiac MR (CMR) and phase-encoded velocity mapping. Exercise CMR images were acquired immediately following supine lower limb exercise using a CMR-compatible cycle ergometer. Computational fluid dynamics simulations were performed to determine power loss of the TCPC anatomies using in vivo anatomies and measured flows. RESULTS: A significant negative linear correlation was observed between indexed power loss at exercise and (a) minute oxygen consumption (r=-0.60, p<0.0005) and (b) work (r=-0.62, p<0.0005) at anaerobic threshold. As cardiac output increased during exercise, indexed power loss increased in an exponential fashion (y=0.9671x(3.0263), p<0.0001). CONCLUSIONS: This is the first study to demonstrate the relationship between power loss and exercise performance with the TCPC being one of the few modifiable factors to allow for improved quality of life. These results suggest that aerobic exercise tolerance in Fontan patients may, in part, be a consequence of TCPC power loss.
Asunto(s)
Tolerancia al Ejercicio , Procedimiento de Fontan , Cardiopatías Congénitas , Ventrículos Cardíacos/anomalías , Esfuerzo Físico , Complicaciones Posoperatorias , Calidad de Vida , Adolescente , Adulto , Velocidad del Flujo Sanguíneo , Gasto Cardíaco , Manejo de la Enfermedad , Prueba de Esfuerzo/métodos , Terapia por Ejercicio/métodos , Femenino , Procedimiento de Fontan/métodos , Procedimiento de Fontan/psicología , Procedimiento de Fontan/rehabilitación , Cardiopatías Congénitas/diagnóstico , Cardiopatías Congénitas/metabolismo , Cardiopatías Congénitas/fisiopatología , Cardiopatías Congénitas/cirugía , Hemodinámica , Humanos , Masculino , Modelación Específica para el Paciente , Pennsylvania , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/fisiopatología , Complicaciones Posoperatorias/prevención & controlRESUMEN
BACKGROUND: As patients with a single-ventricle physiology age, long-term complications inherent to this population become more evident. Previous studies have focused on correlating anatomic and hemodynamic performance, but there is little information of how these variables change with time. Vessel growth and flow rate changes were quantified using cardiac magnetic resonance and their effects on hemodynamics were assessed, which could affect the long-term outcome. METHODS: Forty-eight patients with a lateral tunnel or extracardiac conduit Fontan who underwent two cardiac magnetic resonance scans (average interval, 5.1 ± 2.3 years) were studied. Total cavopulmonary connection anatomic and flow variables were reconstructed and normalized to body surface area(1/2). Total cavopulmonary connection hemodynamic efficiency (indexed power loss) was obtained through computational fluid dynamic modeling. RESULTS: Absolute vessel diameters increased with time, normalized diameters decreased, and vessel mean flow rates remained unchanged. Indexed power loss changed significantly in the cohort, as well as in patients in whom the minimum normalized left pulmonary artery decreased. Age at first scan and connection type (lateral tunnel or extracardiac conduit) were not associated with changes in indexed power loss. CONCLUSIONS: We present the largest serial cardiac magnetic resonance Fontan cohort to date. Although flow rates increased proportionally to body surface area, vessel diameters did not match somatic growth. As a result, energy losses increased significantly with time in the cohort analyzed.
Asunto(s)
Procedimiento de Fontan , Arteria Pulmonar/fisiología , Vena Cava Superior/fisiología , Adolescente , Técnicas de Imagen Cardíaca , Niño , Preescolar , Femenino , Hemodinámica , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , Arteria Pulmonar/crecimiento & desarrollo , Arteria Pulmonar/cirugía , Flujo Sanguíneo Regional , Estudios Retrospectivos , Vena Cava Superior/crecimiento & desarrollo , Vena Cava Superior/cirugíaRESUMEN
OBJECTIVES: To describe the HIV viral load and CD4 cell counts of youth (12-24 years) in 14 cities from March 2010 through November 2011. METHODS: Baseline HIV viral load and CD4 cell count data were electronically abstracted in a central location and in an anonymous manner through a random computer-generated coding system without any ability to link codes to individual cases. RESULTS: Among 1409 HIV reported cases, 852 participants had data on both viral load and CD4 cell counts. Of these youth, 34% had CD4 cell counts of 350 or less, 27% had cell counts from 351 to 500, and 39% had CD4 cell counts greater than 500. Youth whose transmission risk was male-to-male sexual contact had higher viral loads compared with youth whose transmission risk was perinatal or heterosexual contact. Greater than 30% of those who reported male-to-male sexual contact had viral loads greater than 50â000 copies, whereas less than 20% of heterosexual contact youth had viral loads greater than 50â000 copies. There were no differences noted in viral load by type of testing site. CONCLUSION: Most HIV-infected youth have CD4 cell counts and viral load levels associated with high rates of sexual transmission. Untreated, these youth may directly contribute to high rates of ongoing transmission. It is essential that any public health test and treat strategy place a strong emphasis on youth, particularly young MSM.
Asunto(s)
Infecciones por VIH/inmunología , Adolescente , Recuento de Linfocito CD4 , Niño , Ciudades , Femenino , Humanos , Masculino , Conducta Sexual , Carga Viral , Adulto JovenRESUMEN
Incidents of scabies are increasing nationally and globally, particularly among certain vulnerable groups. This article examines a rare and unusual case of scabies infestation in infancy and highlights the importance of recognising the differences in presentation of infestation in infants to enhance early diagnosis and treatment.
Asunto(s)
Escabiosis/diagnóstico , Humanos , LactanteRESUMEN
OBJECTIVES: This study sought to quantify average hemodynamic metrics of the Fontan connection as reference for future investigations, compare connection types (intra-atrial vs extracardiac), and identify functional correlates using computational fluid dynamics in a large patient-specific cohort. Fontan hemodynamics, particularly power losses, are hypothesized to vary considerably among patients with a single ventricle and adversely affect systemic hemodynamics and ventricular function if suboptimal. METHODS: Fontan connection models were created from cardiac magnetic resonance scans for 100 patients. Phase velocity cardiac magnetic resonance in the aorta, vena cavae, and pulmonary arteries was used to prescribe patient-specific time-averaged flow boundary conditions for computational fluid dynamics with a customized, validated solver. Comparison with 4-dimensional cardiac magnetic resonance velocity data from selected patients was used to provide additional verification of simulations. Indexed Fontan power loss, connection resistance, and hepatic flow distribution were quantified and correlated with systemic patient characteristics. RESULTS: Indexed power loss varied by 2 orders of magnitude, whereas, on average, Fontan resistance was 15% to 20% of published values of pulmonary vascular resistance in single ventricles. A significant inverse relationship was observed between indexed power loss and both systemic venous flow and cardiac index. Comparison by connection type showed no differences between intra-atrial and extracardiac connections. Instead, the least efficient connections revealed adverse consequences from localized Fontan pathway stenosis. CONCLUSIONS: Fontan power loss varies from patient to patient, and elevated levels are correlated with lower systemic flow and cardiac index. Fontan connection type does not influence hemodynamic efficiency, but an undersized or stenosed Fontan pathway or pulmonary arteries can be highly dissipative.
Asunto(s)
Procedimiento de Fontan/métodos , Cardiopatías Congénitas/diagnóstico , Cardiopatías Congénitas/cirugía , Hemodinámica , Imagen por Resonancia Magnética/métodos , Modelos Cardiovasculares , Niño , Femenino , Hemorreología , Humanos , MasculinoRESUMEN
Total cavopulmonary connection (TCPC) geometries have great variability. Geometric features, such as diameter, connection angle, and distance between vessels, are hypothesized to affect the energetics and flow dynamics within the connection. This study aimed to identify important geometric characteristics that can influence TCPC hemodynamics. Anatomies from 108 consecutive patients were reconstructed from cardiac magnetic resonance (CMR) images and analyzed for their geometric features. Vessel flow rates were computed from phase contrast CMR. Computational fluid dynamics simulations were carried out to quantify the indexed power loss and hepatic flow distribution. TCPC indexed power loss correlated inversely with minimum Fontan pathway (FP), left pulmonary artery, and right pulmonary artery diameters. Cardiac index correlated with minimum FP diameter and superior vena cava (SVC) minimum/maximum diameter ratio. Hepatic flow distribution correlated with caval offset, pulmonary flow distribution, and the angle between FP and SVC. These correlations can have important implications for future connection design and patient follow-up.
Asunto(s)
Procedimiento de Fontan , Cardiopatías Congénitas/cirugía , Hemodinámica , Arteria Pulmonar/cirugía , Vena Cava Inferior/cirugía , Vena Cava Superior/cirugía , Adolescente , Niño , Preescolar , Simulación por Computador , Femenino , Cardiopatías Congénitas/diagnóstico , Cardiopatías Congénitas/fisiopatología , Humanos , Circulación Hepática , Imagen por Resonancia Magnética , Masculino , Modelos Cardiovasculares , Arteria Pulmonar/patología , Arteria Pulmonar/fisiopatología , Circulación Pulmonar , Resultado del Tratamiento , Vena Cava Inferior/patología , Vena Cava Inferior/fisiopatología , Vena Cava Superior/patología , Vena Cava Superior/fisiopatologíaRESUMEN
BACKGROUND: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biological activity, and is elevated in individuals with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youths treated with combination antiretroviral therapy (cART) containing or not containing TDF. METHODS: A randomized controlled trial in HIV-positive youths aged 18-25 years enrolled participants based on cART treatment with TDF (TDF; n=118) or without TDF (no-TDF; n=85), and randomized within those groups to VITD (50,000 IU every 4 weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. RESULTS: At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was 7.7 pg/ml in the TDF/VITD group, compared with -1.7 (no-TDF/VITD, P=0.010), -1.3 (TDF/PL, P=0.006) and 1.1 (no-TDF/PL, P=0.035). CONCLUSIONS: These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youths. Clinical trials number: NCT00490412.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/uso terapéutico , Colecalciferol/administración & dosificación , Suplementos Dietéticos , Factores de Crecimiento de Fibroblastos/metabolismo , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/metabolismo , Organofosfonatos/uso terapéutico , Adenina/uso terapéutico , Adolescente , Adulto , Colecalciferol/farmacocinética , Femenino , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/sangre , Humanos , Masculino , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Tenofovir , Resultado del Tratamiento , Adulto JovenAsunto(s)
Trastornos de Deglución/diagnóstico , Servicio de Urgencia en Hospital , Exantema/diagnóstico , Antagonistas de los Receptores Histamínicos/administración & dosificación , Linfoma/diagnóstico por imagen , Tos/diagnóstico , Tos/tratamiento farmacológico , Trastornos de Deglución/terapia , Diagnóstico Diferencial , Tratamiento de Urgencia/métodos , Exantema/tratamiento farmacológico , Dermatosis Facial/diagnóstico , Dermatosis Facial/tratamiento farmacológico , Femenino , Humanos , Linfoma/diagnóstico , Linfoma/patología , Radiografía Torácica/métodos , Tomografía Computarizada por Rayos X/métodos , Reino Unido , Adulto JovenRESUMEN
The assessment of suicidal intent in first-contact settings, including the emergency department, can be challenging. Inaccurate assessment can lead to increased incidence of self-harm and completion of suicide. This article focuses on factors that may affect review of this patient group, including healthcare professionals' personal and professional standards and values. Strategies to aid assessment of people presenting with suicidal ideation are discussed.
Asunto(s)
Servicios Médicos de Urgencia/organización & administración , Ideación Suicida , Educación Continua , Humanos , Reino UnidoRESUMEN
Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study of HIV-infected youth on stable treatment with regimens containing TDF (n = 118) or lacking TDF (n = 85), we measured cross-sectional associations of TDF use with markers of renal function, vitamin D-calcium-parathyroid hormone balance, phosphate metabolism (tubular reabsorption of phosphate and fibroblast growth factor 23 [FGF23]), and bone turnover. Pharmacokinetic-pharmacodynamic associations with plasma tenofovir and intracellular tenofovir diphosphate concentrations were explored among those receiving TDF. The mean age was 20.9 (standard deviation [SD], 2.0) years; 63% were male; and 52% were African American. Compared to the no-TDF group, the TDF group showed lower mean estimated glomerular filtration rates and tubular reabsorption of phosphate, as well as higher parathyroid hormone and 1,25-dihydroxy vitamin D [1,25-OH(2)D] levels. The highest quintile of plasma tenofovir concentrations was associated with higher vitamin D binding protein, lower free 1,25-OH(2)D, higher 25-OH vitamin D, and higher serum calcium. The highest quintile of intracellular tenofovir diphosphate concentration was associated with lower FGF23. Higher plasma tenofovir concentrations were associated with higher vitamin D binding protein and lower free 1,25-OH(2)D, suggesting a functional vitamin D deficiency explaining TDF-associated increased parathyroid hormone. The finding of lower FGF23 accompanying higher intracellular tenofovir diphosphate suggests that different mechanisms mediate TDF-associated changes in phosphate handling. Separate pharmacokinetic properties may be associated with distinct TDF toxicities: tenofovir with parathyroid hormone and altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23 regulation. (The clinical trial registration number for this study is NCT00490412 and is available online at http://clinicaltrials.gov/ct2/show/NCT00490412.).